1. Research Methodology

2. Executive Summary

3. Strategic Recommendations

4. Hepatitis B Treatment Market: Product Outlook

5. Global Hepatitis B Treatment Market: Growth and Forecast
5.1. Global Hepatitis B Treatment Market, By Value (2012-2016)
5.2. Global Hepatitis B Treatment Market, By Value (2017-2022)
5.3. Global Hepatitis B Treatment Market - By Type, By Value
5.3.1. Global Hepatitis B Treatment Market, By Value, % (2016)
5.3.2. Global Hepatitis B Treatment Market, By Value, % (Forecast 2022F)
5.4. Global Hepatitis B Treatment Market, By Type, By Value (2012-2022)
5.4.1. Therapeutics, By Value (2012-2022)
5.4.2. Vaccines, By Value (2012-2022)
5.5. Global Hepatitis B Treatment Market, By End-User, By Value (2012-2022)
5.5.1. Male, By Value (2012-2022)
5.5.2. Female, By Value (2012-2022)

6. North America Hepatitis B Treatment Market: Growth and Forecast
6.1. North America Hepatitis B Treatment Market, By Value (2012-2016)
6.2. North America Hepatitis B Treatment Market, By Value (2017-2022)
6.3. North America Hepatitis B Treatment Market - By Type, By Value
6.3.1. North America Hepatitis B Treatment Market, By Value, % (2016)
6.3.2. North America Hepatitis B Treatment Market, By Value, % (Forecast 2022F)
6.4. North America Hepatitis B Treatment Market, By Type, By Value (2012-2022)
6.4.1. Therapeutics, By Value (2012-2022)
6.4.2. Vaccines, By Value (2012-2022)
6.5. North America Hepatitis B Treatment Market, By End-User, By Value (2012-2022)
6.5.1. Male, By Value (2012-2022)
6.5.2. Female, By Value (2012-2022)

6.6. North America Hepatitis B Treatment Market: Country Analysis (U.S., Canada)
6.6.1. North America Hepatitis B Treatment Market, Country Share, 2016 (% of Total)
6.6.2. North America Hepatitis B Treatment Market, Country Share, 2022 (% of Total)

6.7. U.S. Hepatitis B Treatment Market: Growth and Forecast
6.7.1. U.S. Hepatitis B Treatment Market, By Value (2012-2016)
6.7.2. U.S. Hepatitis B Treatment Market, By Value (2017-2022)
6.8. U.S. Hepatitis B Treatment Market - By Type, By Value
6.8.1. Therapeutics, By Value (2012-2022)
6.8.2. Vaccines, By Value (2012-2022)
6.9. U.S. Hepatitis B Treatment Market - By End-User, By Value
6.9.1. Male, By Value (2012-2022)
6.9.2. Female, By Value (2012-2022)

6.10. Canada Hepatitis B Treatment Market: Growth and Forecast
6.10.1. Canada Hepatitis B Treatment Market, By Value (2012-2016)
6.10.2. Canada Hepatitis B Treatment Market, By Value (2017-2022)
6.11. Canada Hepatitis B Treatment Market - By Type, By Value
6.11.1. Therapeutics, By Value (2012-2022)
6.11.2. Vaccines, By Value (2012-2022)
6.12. Canada Hepatitis B Treatment Market - By End-User, By Value
6.12.1. Male, By Value (2012-2022)
6.12.2. Female, By Value (2012-2022)

7. Europe Hepatitis B Treatment Market: Growth and Forecast
7.1. Europe Hepatitis B Treatment Market, By Value (2012-2016)
7.2. Europe Hepatitis B Treatment Market, By Value (2017-2022)
7.3. Europe Hepatitis B Treatment Market - By Type, By Value
7.3.1. Europe Hepatitis B Treatment Market, By Value, % (2016)
7.3.2. Europe Hepatitis B Treatment Market, By Value, % (Forecast 2022F)
7.4. Europe Hepatitis B Treatment Market, By Type, By Value (2012-2022)
7.4.1. Therapeutics, By Value (2012-2022)
7.4.2. Vaccines, By Value (2012-2022)
7.5. Europe Hepatitis B Treatment Market, By End-User, By Value (2012-2022)
7.5.1. Male, By Value (2012-2022)
7.5.2. Female, By Value (2012-2022)

7.6. Euope Hepatitis B Treatment Market: Country Analysis (U.K., Germany, France)
7.6.1. Europe Hepatitis B Treatment Market, Country Share, 2016 (% of Total)
7.6.2. Europe Hepatitis B Treatment Market, Country Share, 2022 (% of Total)

7.7. U.K. Hepatitis B Treatment Market: Growth and Forecast
7.7.1. U.K. Hepatitis B Treatment Market, By Value (2012-2016)
7.7.2. U.K. Hepatitis B Treatment Market, By Value (2017-2022)
7.8. U.K. Hepatitis B Treatment Market - By Type, By Value
7.8.1. Therapeutics, By Value (2012-2022)
7.8.2. Vaccines, By Value (2012-2022)
7.9. U.K. Hepatitis B Treatment Market - By End-User, By Value
7.9.1. Male, By Value (2012-2022)
7.9.2. Female, By Value (2012-2022)

7.10. Germany Hepatitis B Treatment Market: Growth and Forecast
7.10.1. Germany Hepatitis B Treatment Market, By Value (2012-2016)
7.10.2. Germany Hepatitis B Treatment Market, By Value (2017-2022)
7.11. Germany Hepatitis B Treatment Market - By Type, By Value
7.11.1. Therapeutics, By Value (2012-2022)
7.11.2. Vaccines, By Value (2012-2022)
7.12. Germany Hepatitis B Treatment Market - By End-User, By Value
7.12.1. Male, By Value (2012-2022)
7.12.2. Female, By Value (2012-2022)

7.13. France Hepatitis B Treatment Market: Growth and Forecast
7.13.1. France Hepatitis B Treatment Market, By Value (2012-2016)
7.13.2. France Hepatitis B Treatment Market, By Value (2017-2022)
7.14. France Hepatitis B Treatment Market - By Type, By Value
7.14.1. Therapeutics, By Value (2012-2022)
7.14.2. Vaccines, By Value (2012-2022)
7.15. France Hepatitis B Treatment Market - By End-User, By Value
7.15.1. Male, By Value (2012-2022)
7.15.2. Female, By Value (2012-2022)

8. Asia-Pacific Hepatitis B Treatment Market: Growth and Forecast
8.1. Asia-Pacific Hepatitis B Treatment Market, By Value (2012-2016)
8.2. Asia-Pacific Hepatitis B Treatment Market, By Value (2017-2022)
8.3. Asia-Pacific Hepatitis B Treatment Market - By Type, By Value
8.3.1. Asia-Pacific Hepatitis B Treatment Market, By Value, % (2016)
8.3.2. Asia-Pacific Hepatitis B Treatment Market, By Value, % (Forecast 2022F)
8.4. Asia-Pacific Hepatitis B Treatment Market, By Type, By Value (2012-2022)
8.4.1. Therapeutics, By Value (2012-2022)
8.4.2. Vaccines, By Value (2012-2022)
8.5. Asia-Pacific Hepatitis B Treatment Market, By End-User, By Value (2012-2022)
8.5.1. Male, By Value (2012-2022)
8.5.2. Female, By Value (2012-2022)

8.6. Asia-Pacific Hepatitis B Treatment Market: Country Analysis (Japan, China, India)
8.6.1. Asia-Pacific Hepatitis B Treatment Market, Country Share, 2016 (% of Total)
8.6.2. Asia-Pacific Hepatitis B Treatment Market, Country Share, 2022 (% of Total)

8.7. Japan Hepatitis B Treatment Market: Growth and Forecast
8.7.1. Japan Hepatitis B Treatment Market, By Value (2012-2016)
8.7.2. Japan Hepatitis B Treatment Market, By Value (2017-2022)
8.8. Japan Hepatitis B Treatment Market - By Type, By Value
8.8.1. Therapeutics, By Value (2012-2022)
8.8.2. Vaccines, By Value (2012-2022)
8.9. Japan Hepatitis B Treatment Market - By End-User, By Value
8.9.1. Male, By Value (2012-2022)
8.9.2. Female, By Value (2012-2022)

8.10. China Hepatitis B Treatment Market: Growth and Forecast
8.10.1. China Hepatitis B Treatment Market, By Value (2012-2016)
8.10.2. China Hepatitis B Treatment Market, By Value (2017-2022)
8.11. China Hepatitis B Treatment Market - By Type, By Value
8.11.1. Therapeutics, By Value (2012-2022)
8.11.2. Vaccines, By Value (2012-2022)
8.12. China Hepatitis B Treatment Market - By End-User, By Value
8.12.1. Male, By Value (2012-2022)
8.12.2. Female, By Value (2012-2022)

8.13. India Hepatitis B Treatment Market: Growth and Forecast
8.13.1. India Hepatitis B Treatment Market, By Value (2012-2016)
8.13.2. India Hepatitis B Treatment Market, By Value (2017-2022)
8.14. India Hepatitis B Treatment Market - By Type, By Value
8.14.1. Therapeutics, By Value (2012-2022)
8.14.2. Vaccines, By Value (2012-2022)
8.15. India Hepatitis B Treatment Market - By End-User, By Value
8.15.1. Male, By Value (2012-2022)
8.15.2. Female, By Value (2012-2022)

9. ROW Hepatitis B Treatment Market: Growth and Forecast
9.1. ROW Hepatitis B Treatment Market, By Value (2012-2016)
9.2. ROW Hepatitis B Treatment Market, By Value (2017-2022)

10. Market Dynamics
10.1. Increasing prevalence of Liver diseases due to Hepatitis B
10.2. Increasing awareness about the Hepatitis B & HBV
10.3. Rising healthcare expenditure worldwide

11. Market Restraints

12. SWOT Analysis – Hepatitis B Treatment Market

13. Porter’s Five Forces Analysis

14. Policy and Regulations

15. Global Hepatitis B Drugs Pipeline

16. Global Hepatitis B Treatment Market - Competitive Landscape

17. Company Profiles
17.1. Merck and Co
17.2. Gilead Sciences
17.3. Novartis AG
17.4. GlaxoSmithKline, plc
17.5. F.Hoffmann- La Roche
17.6. Bristol-Myers Squibb
17.7. AbbVie Inc

List of Figures
Figure 1: Global Hepatitis B Treatment Market Size, By Value, 2012-2016 (USD Million)
Figure 2: Number of patients with Hepatitis B Virus (HBsAg) infection by WHO region, 2015 (In Million)
Figure 3: Global Healthcare Expenditure, 2012-2016 (In Trillion)
Figure 4: Global Hepatitis B Treatment Market Size, By Value, 2017-2022 (USD Million)
Figure 5: Global Hepatitis B Treatment Market Size, By Type, 2016 (%)
Figure 6: Global Hepatitis B Treatment Market Size, By Type, 2022 (%)
Figure 7: Global Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million)
Figure 8: Global Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
Figure 9: Global Sales of HBV approved Drugs, By Value, 2014-2016 (USD Million)
Figure 10: Global Sales of Viread, By Value, 2015-2016 (USD Million)
Figure 11: Global Hepatitis B Treatment Market Size, By Region, 2016 (%)
Figure 12: Global Hepatitis B Treatment Market Size, By Region, 2022 (%)
Figure 13: North America Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million)
Figure 14: North America GDP, 2012-2015 (USD Trillion)
Figure 15: North America GDP, By Select Country, 2016 (USD Trillion)
Figure 16: Population aged 65 & above, 2012-2016 (% of total)
Figure 17: North America Hepatitis B Treatment Market Size, By Type, 2016 (%)
Figure 18: North America Hepatitis B Treatment Market Size, By Type, 2022 (%)
Figure 19: North America Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million)
Figure 20: North America Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
Figure 21: North America Hepatitis B Treatment Market, Country Share, 2016 (% of Total)
Figure 22: North America Hepatitis B Treatment Market, Country Share, 2022 (% of Total)
Figure 23: U.S. Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million)
Figure 24: U.S. Per Capita Healthcare Expenditure, 2012-2016 (In USD)
Figure 25: Reported acute (new) cases of Hepatitis B Virus in U.S., (2012-2015)
Figure 26: Incidences rate of acute Hepatitis B in U.S., By sex (2012-2015)
Figure 27: Incidence of acute Hepatitis B in U.S., By age group, (2012-2015)
Figure 28: U.S. Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million)
Figure 29: U.S. Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
Figure 30: Market Share of HBV approved Drugs in U.S., 2016 (% Share)
Figure 31: Canada Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million)
Figure 32: Canada Per Capita Healthcare Expenditure, 2012-2016 (In USD)
Figure 33: Canada Life Expectancy at birth rate (Years), 2012-2015
Figure 34: Prevalence of Hepatitis B in Canada, (Patients per 100,000 (2012-2016)
Figure 35: Number of Hepatitis B Patients, Canada, (2013-2016)
Figure 36: Prevalence of Hepatitis B among Male population, Canada, (Patients per 100,000) (2012-2016)
Figure 37: Prevalence of Hepatitis B among Female population, Canada, (Patients per 100,000) (2012-2016)
Figure 38: Canada Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million)
Figure 39: Canada Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
Figure 40: Europe Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million)
Figure 41: European Union, Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 42: European Union Life Expectancy at birth rate (Years), 2012-2015
Figure 43: Reported Hepatitis B Cases, Number & Rate per 100,000 populations, EU/EEA, 2012-2015
Figure 44: Acute & Chronic Hepatitis B cases, rate per 100,000 populations, By Age Group, 2015
Figure 45: Acute & Chronic Hepatitis B cases, rate per 100,000 populations, By Age Group, 2015
Figure 46: Europe Hepatitis B Treatment Market Size, By Type, 2016 (%)
Figure 47: Europe Hepatitis B Treatment Market Size, By Type, 2022 (%)
Figure 48: Europe Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million)
Figure 49: Europe Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
Figure 50: Europe Hepatitis B Treatment, Country Share, 2016 (% of Total)
Figure 51: Europe Hepatitis B Treatment, Country Share, 2022 (% of Total)
Figure 52: U.K. Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Figure 53: U.K. Population 65 Years & Above (% of Total), 2012-2016
Figure 54: U.K. Life Expectancy at birth rate (Years), 2012-2015
Figure 55: U.K. Women Population, 2012-2016
Figure 56: U.K., Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 57: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
Figure 58: Number of Hepatitis B Patients, (2013-2016)
Figure 59: Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016)
Figure 60: Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016)
Figure 61: U.K. Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
Figure 62: U.K. Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
Figure 63: Germany Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Figure 64: Germany Population 65 Years & Above (% of Total), 2012-2016
Figure 65: Germany Life Expectancy at birth rate (Years), 2012-2015
Figure 66: Germany Women Population, 2012-2016
Figure 67: Germany Per Capita Healthcare Expenditure, 2012 - 2014 (In USD)
Figure 68: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
Figure 69: Number of Hepatitis B Patients, (2013-2016)
Figure 70: Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016)
Figure 71: Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016)
Figure 72: Germany Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
Figure 73: Germany Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
Figure 74: France Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Figure 75: France Population 65 Years & Above (% of Total), 2012-2016
Figure 76: France Life Expectancy at birth rate (Years), 2012-2015
Figure 77: France Women Population, 2012-2016
Figure 78: France Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 79: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
Figure 80: Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016)
Figure 81: Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016)
Figure 82: France Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
Figure 83: France Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
Figure 84: Asia-Pacific Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Figure 85: Mortality due to Viral Hepatitis in South-East Asia region, 2015
Figure 86: Asia-Pacific Hepatitis B Treatment Size, By Type, 2016 (%)
Figure 87: Asia-Pacific Hepatitis B Drug Market Size, By Type, 2022 (%)
Figure 88: Asia-pacific Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
Figure 89: Asia-Pacific Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
Figure 90: Asia-Pacific Hepatitis B Treatment, Country Share, 2016 (% of Total)
Figure 91: Asia-Pacific Hepatitis B Treatment, Country Share, 2022 (% of Total)
Figure 92: Japan Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Figure 93: Japan Population 65 Years & Above (% of Total), 2012-2016
Figure 94: Japan Life Expectancy at birth rate (Years), 2012-2015
Figure 95: Japan, Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 96: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
Figure 97: Number of Hepatitis B Patients, 2013-2016)
Figure 98: Prevalence of Hepatitis B among Male population (Patients per 100,000 (2012-2016)
Figure 99: Prevalence of Hepatitis B among Female population (Patients per 100,000 (2012-2016)
Figure 100: Japan Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
Figure 101: Japan Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
Figure 102: China Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Figure 103: China Population 65 Years & Above (% of Total), 2012-2016
Figure 104: China Life Expectancy at birth rate (Years), 2012-2015
Figure 105: China Women Population, 2012-2016
Figure 106: China Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 107: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
Figure 108: Number of Hepatitis B Patients, 2013-2016)
Figure 109: Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016)
Figure 110: Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016)
Figure 111: China Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
Figure 112: China Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
Figure 113: India Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Figure 114: India Population 65 Years & Above (% of Total), 2012-2016
Figure 115: India Life Expectancy at birth rate (Years), 2012-2015
Figure 116: India Women Population, 2012-2016
Figure 117: India Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 118: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
Figure 119: Number of Hepatitis B Patients, 2013-2016)
Figure 120: Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016)
Figure 121: Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016)
Figure 122: India Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
Figure 123: India Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
Figure 124: ROW Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Figure 125: Prevalence of Hepatitis B in Brazil (Patients per 100,000 (2012-2016)
Figure 126: Number of Hepatitis B Patients in Brazil, (2013-2016)
Figure 127: Prevalence of Hepatitis B among Male population, in Brazil (Patients per 100,000) (2012-2016)
Figure 128: Prevalence of Hepatitis B among Female population in Brazil (Patients per 100,000) (2012-2016)
Figure 129: Prevalence of Hepatitis B in South Africa (Patients per 100,000 (2012-2016)
Figure 130: Number of Hepatitis B Patients in South Africa, (2013-2016)
Figure 131: Prevalence of Hepatitis B among Male population, in South Africa (Patients per 100,000) (2012-2016)
Figure 132: Prevalence of Hepatitis B among Female population (Patients per 100,000), in South Africa (2012-2016)
Figure 133: Global Healthcare Expenditure, 2012-2016 (In Trillion)
Figure 134: Global Sales of HBV approved Drugs, By Value, 2014-2016 (USD Million)
Figure 135: Global Sales of Viread, By, Region, By Value, 2015-2016 (USD Million)
Figure 136: Merck & Co., Net Sales, 2012-2016 (In million USD)
Figure 137: Merck & Co, Net Sales of Gardasil/Gardasil 9, 2012-2016 (In million USD)
Figure 138: Merck & Co., Net Sales, By Geographic Location, % Share 2016
Figure 139: Merck & Co., Net Revenue, By Business Segment, % Share 2016
Figure 140: Gilead Sciences Annual Revenue, 2014-2016 (USD Million)
Figure 141: Gilead Sciences HBV Product Sales, 2014-2016 (USD Million)
Figure 142: Gilead Sciences Revenue by Geographical, 2016 (%)
Figure 143: Gilead Sciences Product Sales, 2016 (%)
Figure 144: Novartis Annual Revenue, 2014-2016 (USD Million)
Figure 145: Innovative Medicine Net Sales, By Business Unit 2016 (%)
Figure 146: Novartis Sales, By Region, 2016 (%)
Figure 147: Novartis Sales, By Segment 2016 (%)
Figure 148: GlaxoSmithKline Annual Revenue, 2014-2016 (USD Million)
Figure 149: Sales from Hepatitis Vaccination, GlaxoSmithKline, 2015 - 2016 (USD Million)
Figure 150: Glaxosmithkline Sales, By Region, 2016 (%)
Figure 151: Glaxosmithkline, Sales, By Segment 2016 (%)
Figure 152: F. Hoffmann-La Roche Ltd Annual Revenue, 2014-2016 (USD Million)
Figure 153: F. Hoffmann-La Roche Ltd Segmental Break Up, By Revenue, By Business Division, 2016 (%)
Figure 154: F. Hoffmann-La Roche Ltd Geographical Break Up, By Revenue, 2016 (%)
Figure 155: Bristol-Myers Squibb Company Annual Revenue, 2014-2016 (USD Million)
Figure 156: Bristol-Myers Squibb Company Segmental Break Up, By Revenue, By Products, 2016 (%)
Figure 157: Bristol-Myers Squibb Company Geographical Break Up, By Revenue, 2016 (%)
Figure 158: Baraclude (entecavir), Annual Revenue, 2014-2016 (USD Million)
Figure 159: Baraclude (entecavir), Segmental Break Up, By geographical segment, 2016 (%)
Figure 160: AbbVie Revenue, Segmental Break Up, 2016
Figure 161: AbbVie Revenue, Geographical Break Up, 2016

List of Tables
Table A: Causes of Hepatitis B
Table B: HBV Approved Therapies
Table C: Globally Approved HBV Monovalent Vaccines
Table D: Compounds in development for chronic Hepatitis B